A study by Yoshida et al. demonstrated in early-stage gastric cancer, the CD47 positivity rate was 49.5%, and the 5-year survival rate of the CD47-positive subgroup was remarkably lower than that of the CD47-negative subgroup (Mittrücker et al., 2014). Here, CD47 is linked to gastric cancer.